Carmot Therapeutics, Inc.

Carmot Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for metabolic diseases, primarily obesity and diabetes. Carmot's approach is based on the manipulation of incretins, gut hormones that play a crucial role in regulating blood sugar and energy balance. Their unique drug discovery platform, Chemotype Evolution, enables the efficient identification and optimization of drug candidates by iteratively synthesizing and screening chemical libraries. Carmot has a robust pipeline of three clinical candidates: CT-388, a once-weekly injectable dual GLP-1/GIP receptor agonist for obesity; CT-868, a once-daily injectable dual GLP-1/GIP receptor agonist for type 1 diabetes; and CT-996, an oral small molecule GLP-1 receptor agonist for obesity and type 2 diabetes.

In early 2024, Carmot was acquired by the Roche Group, becoming part of their Pharmaceuticals Division. This acquisition highlights the significant potential of Carmot's innovative approach to treating metabolic disorders and reflects Roche's commitment to developing new therapies for these prevalent diseases.

Carmot Therapeutics is a clinical-stage biotechnology company dedicated to developing life-changing treatments for people living with metabolic diseases, particularly obesity and diabetes. They are committed to addressing the global health challenges posed by these conditions through their focus on developing innovative therapies that modulate gut hormones, ultimately aiming to improve clinical outcomes and enhance the lives of those impacted by metabolic disorders.

Carmot Therapeutics promotes a culture focused on innovation and collaboration, driven by a shared vision of creating a healthier future. They are committed to developing disease-modifying therapies for people living with metabolic diseases, emphasizing their dedication to improving clinical outcomes for individuals facing challenges like obesity and diabetes. Their team is composed of talented individuals who share this vision and work together to achieve their goals.